MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) represents one of the most significant discoveries in mitochondrial biology of the past decade. First identified in 2015 by Changhan Lee and colleagues at the University of Southern California, MOTS-c is a 16-amino acid peptide (sequence: MRWQEMGYIFYPRKLR) encoded within the mitochondrial 12S rRNA gene. Its discovery fundamentally expanded our understanding of the mitochondrial genome — previously considered primarily a blueprint for oxidative phosphorylation components — by revealing it as a source of bioactive signaling peptides that regulate nuclear gene expression and systemic metabolism.
Discovery and the Mitochondrial-Derived Peptide Concept
The concept of mitochondrial-derived peptides (MDPs) emerged from the discovery of humanin in 2001 (Hashimoto et al., Proceedings of the National Academy of Sciences), a 24-amino acid peptide encoded in the 16S rRNA gene of the mitochondrial genome that showed neuroprotective properties. MOTS-c was the second MDP to be identified, discovered through a systematic analysis of small open reading frames (sORFs) within the mitochondrial genome.
Lee et al. (2015, Cell Metabolism) identified MOTS-c by screening the mitochondrial genome for previously unrecognized sORFs that could encode functional peptides. The MOTS-c coding sequence resides within the 12S rRNA gene (MT-RNR1) and is translated in the cytoplasm using the mitochondrial genetic code after the mRNA is exported from the mitochondria. This discovery was remarkable because it demonstrated retrograde signaling from the mitochondrial genome to the nucleus — a form of "mitonuclear communication" that adds a new dimension to our understanding of how mitochondria influence cellular function.
Molecular Mechanism: AMPK Pathway Activation
The primary molecular mechanism identified for MOTS-c action is activation of the AMPK (AMP-activated protein kinase) signaling pathway, the master energy sensor of the cell. Lee et al. (2015) demonstrated that MOTS-c treatment in cell culture activates AMPK through a mechanism involving the folate-methionine cycle.
Specifically, MOTS-c inhibits the de novo purine biosynthesis pathway by interfering with the folate cycle enzyme ATIC (5-aminoimidazole-4-carboxamide ribonucleotide formyltransferase). This leads to accumulation of the AMPK activator AICAR (5-aminoimidazole-4-carboxamide ribonucleoside) in the cell. The resulting AMPK activation triggers a cascade of downstream effects:
Increased glucose uptake: AMPK activation promotes GLUT4 translocation to the cell membrane, increasing cellular glucose uptake independent of insulin signaling.
Enhanced fatty acid oxidation: AMPK phosphorylates and inactivates acetyl-CoA carboxylase (ACC), reducing malonyl-CoA levels and relieving inhibition of carnitine palmitoyltransferase 1 (CPT1), the rate-limiting enzyme for mitochondrial fatty acid import.
Suppression of de novo lipogenesis: AMPK-mediated inactivation of ACC simultaneously reduces substrate availability for fatty acid synthesis.
Activation of PGC-1alpha: AMPK phosphorylation of PGC-1alpha promotes mitochondrial biogenesis, creating a positive feedback loop where a mitochondrial-derived peptide enhances mitochondrial capacity.
MOTS-c and Metabolic Regulation
The metabolic effects of MOTS-c have been documented in multiple independent studies across different animal models. In the original characterization, Lee et al. (2015) showed that:
Prevention of diet-induced obesity: Mice receiving daily intraperitoneal MOTS-c injections (5 mg/kg) while fed a high-fat diet gained significantly less weight than control animals, with reduced fat mass accumulation despite equivalent caloric intake. This weight difference was attributable to increased energy expenditure rather than reduced food consumption.
Improved glucose homeostasis: MOTS-c treatment improved glucose tolerance and insulin sensitivity in both diet-induced obese mice and genetically obese (ob/ob) mice. Fasting blood glucose levels were significantly lower in treated animals, and glucose tolerance tests showed faster glucose clearance.
Increased skeletal muscle glucose utilization: MOTS-c treatment enhanced skeletal muscle glucose uptake through AMPK-dependent GLUT4 translocation, shifting the metabolic phenotype toward increased glucose utilization and reduced reliance on fatty acid oxidation under high-fat feeding conditions.
MOTS-c and Aging
MOTS-c levels have been shown to decline with age in both animal models and human subjects, paralleling the decline in mitochondrial function that characterizes aging. Kim et al. (2018, Journal of the American Geriatrics Society) measured circulating MOTS-c levels in a cohort of Japanese adults and found significant age-dependent decline, with the lowest levels in individuals over 70 years of age.
Reynolds et al. (2021, Nature Communications) conducted a pivotal study demonstrating that MOTS-c treatment could improve physical function in aged mice. Mice treated with MOTS-c at 23.5 months of age (equivalent to approximately 70 human years) showed improved physical capacity on treadmill testing, enhanced thermoregulation, and better metabolic parameters compared to age-matched controls. Critically, the beneficial effects were observed even when treatment was initiated in old age, suggesting that MOTS-c repletion in aged organisms can partially reverse age-associated functional decline.
The age-related decline in MOTS-c has been attributed to reduced mitochondrial transcription and translation with aging, as well as the progressive accumulation of mitochondrial DNA damage that may specifically affect the 12S rRNA gene region where MOTS-c is encoded. Heteroplasmic mitochondrial DNA mutations in this region have been associated with altered MOTS-c production in cellular models.
MOTS-c Nuclear Translocation: Stress Response
A groundbreaking finding by Kim et al. (2018, Cell Metabolism) revealed that MOTS-c translocates to the nucleus under metabolic stress conditions. Using confocal microscopy and cellular fractionation, they showed that MOTS-c moves from the cytoplasm to the nucleus in response to glucose deprivation, oxidative stress, and serum starvation.
Once in the nucleus, MOTS-c interacts with chromatin and regulates gene expression. Chromatin immunoprecipitation sequencing (ChIP-seq) revealed that nuclear MOTS-c binds to ARE (antioxidant response element) motifs, promoting the expression of genes involved in the cellular antioxidant defense system including NRF2 target genes. This nuclear function of MOTS-c establishes it as a direct link between mitochondrial stress sensing and nuclear transcriptional adaptation — a "mitokine" that coordinates cellular stress responses across organellar boundaries.
MOTS-c and Exercise Biology
MOTS-c has been characterized as an "exercise mimetic" based on its ability to replicate several molecular signatures of physical exercise. Reynolds et al. (2021) showed that acute exercise increases circulating MOTS-c levels in both mice and humans. In the human cohort, a single bout of moderate-intensity exercise increased plasma MOTS-c by approximately 50% within 30 minutes, returning to baseline within 4 hours.
The exercise-mimetic properties of MOTS-c are discussed in greater detail in our companion article on MOTS-c as an exercise mimetic.
MOTS-c in Insulin Resistance and Type 2 Diabetes Research
The insulin-sensitizing properties of MOTS-c have attracted significant attention for metabolic disease research. In addition to the original findings by Lee et al. (2015) in diet-induced obese mice, subsequent studies have expanded the evidence base:
Ming et al. (2016, Obesity) demonstrated that MOTS-c treatment improved insulin signaling in skeletal muscle cells by promoting Akt phosphorylation and GLUT4 translocation through an AMPK-dependent mechanism. This insulin-independent glucose uptake pathway has implications for research on insulin-resistant states where canonical insulin signaling is impaired.
Lu et al. (2019, Molecules) showed that MOTS-c protected pancreatic beta cells from lipotoxicity-induced apoptosis in vitro, suggesting a potential role in preserving beta cell mass under metabolic stress conditions relevant to type 2 diabetes pathogenesis.
MOTS-c and Bone Metabolism
Emerging research has identified effects of MOTS-c on bone metabolism. Hu and Li (2022, Journal of Bone and Mineral Metabolism) demonstrated that MOTS-c promoted osteoblast differentiation and inhibited osteoclastogenesis in cell culture systems. The mechanism involved AMPK-mediated regulation of the Wnt/beta-catenin signaling pathway. These findings suggest that the age-related decline in MOTS-c may contribute to age-associated bone loss, though in vivo studies are needed to confirm this relationship.
Technical Research Considerations
MOTS-c is supplied as a synthetic 16-amino acid peptide (MRWQEMGYIFYPRKLR) in lyophilized form. The molecular weight is 2174.6 Da. For research use:
Reconstitution: Dissolve in sterile water or PBS. MOTS-c is water-soluble at concentrations up to 1 mg/mL. For higher concentrations, brief sonication in a water bath may be required.
Dosing in published studies: The majority of in vivo studies have used 5 mg/kg/day via intraperitoneal injection in mouse models. Cell culture studies typically use concentrations of 1-10 micromolar.
Storage: Lyophilized MOTS-c is stable at -20 degrees Celsius for up to 24 months. Reconstituted solutions should be stored at -20 degrees Celsius in single-use aliquots to avoid freeze-thaw degradation. Working solutions are stable at 4 degrees Celsius for up to 7 days.
Conclusion
MOTS-c has emerged as one of the most promising molecules in metabolic and aging research since its discovery in 2015. As a mitochondrial-derived peptide that activates AMPK, translocates to the nucleus under stress, regulates glucose metabolism, improves insulin sensitivity, mimics exercise signaling, and declines with age, MOTS-c sits at the intersection of multiple major research themes in modern biology. The growing body of published literature — spanning metabolism, aging, exercise physiology, and bone biology — provides a compelling foundation for continued investigation into this remarkable mitochondrial signal.
All research cited refers to published preclinical and clinical studies. MOTS-c is sold by Pepspan strictly for research purposes only.